Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Simbols: 2196.HK

HKSE

13.28

HKD

Tirgus cena šodien

  • 15.5749

    P/E koeficients

  • 7.2266

    PEG koeficients

  • 63.71B

    MRK Cap

  • 0.04%

    DIV ienesīgums

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196-HK) Finanšu pārskati

Diagrammā redzami noklusējuma skaitļi dinamikā attiecībā uz Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK). Uzņēmuma ieņēmumi rāda vidējo NaN M, kas ir NaN % gowth. Vidējā bruto peļņa par visu periodu ir NaN M, kas ir NaN %. Vidējais bruto peļņas koeficients ir NaN %. Uzņēmuma neto ienākumu pieaugums pagājušajā gadā ir NaN %, kas ir vienāds ar NaN % % vidēji visā uzņēmuma vēsturē.,

Bilance

Ledziļinoties uzņēmuma Shanghai Fosun Pharmaceutical (Group) Co., Ltd. fiskālajā trajektorijā, mēs novērojam vidējo aktīvu pieaugumu. Interesanti, ka šis rādītājs ir , kas atspoguļo gan uzņēmuma augstākos, gan zemākos rādītājus. Salīdzinot ar iepriekšējo ceturksni, šis rādītājs tiek pielāgots . Atskats uz pagājušo gadu atklāj kopējās aktīvu izmaiņas NaN apmērā. Akcionāru vērtība, ko atspoguļo kopējais akcionāru pašu kapitāls, tiek novērtēta kā NaN pārskata valūtā. Šā aspekta izmaiņas gada laikā ir NaN%.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

balance-sheet.row.cash-and-short-term-investments

015582.117169.814549.2
11931.9
9989.9
9162.6
7468.2
6044.5
4062.4
3729.5
3111.6
5197.4
3125.9
3562.3
1308.5
1005.7
1079.6
991.3
752.9
688.1
1242.6
629.4
373.1
343.4
170
329.8
25.3
6.6
7.2

balance-sheet.row.short-term-investments

01888.5928.54241.1
1970.1
456.7
616.1
219.3
48.5
33.8
33.8
44.2
224.8
231.3
218.8
11.7
0.1
5.8
2.1
0
5.2
0.2
285.3
0.9
0
0
0
0
0
0

balance-sheet.row.net-receivables

09967.910797.89517.7
7256.7
5873.4
5255.7
4522.5
2976.9
2518.7
3318.7
2256.4
1906.4
1797.3
1426.6
925.2
940.2
732.1
811
673.6
618.3
536.6
406.4
545.2
37.5
58.4
31.4
9.1
5.1
26.3

balance-sheet.row.inventory

07537.86882.45472.3
5162.8
3940.5
3287.4
2750.5
1670.7
1648.8
1604.6
1614.3
1273.4
1123.9
934.4
598
530.5
494.8
607.6
532
472.8
305.1
355.3
120.5
82.8
85
52.3
49.6
18
12.5

balance-sheet.row.other-current-assets

0704.8429.1885.4
733.4
599.5
296
315.3
72.1
95.5
11.2
4.2
4.3
1.9
14.3
475.2
-59.2
210.6
6.5
3.3
0.5
19
16.1
6
207.7
117
96.6
132.7
77
57.4

balance-sheet.row.total-current-assets

033792.635279.230424.6
25084.8
20403.4
18001.7
15056.5
10764.3
8325.4
8664
6986.5
8381.5
6049.1
5937.7
3306.9
2417.3
2517.1
2416.4
1961.9
1779.7
2103.4
1407.2
1044.9
671.4
430.5
510.1
216.7
106.7
103.4

balance-sheet.row.property-plant-equipment-net

022239.416028.113283.9
13002.7
11085.1
9123.1
8315.9
6304.7
5764.9
5681.4
4907.5
3479.7
2627.3
1695.7
1258.8
1145.3
1139.1
1274.4
1240.6
1054
777.2
570.5
349.4
260.6
175.5
74.4
41.6
4.4
3.3

balance-sheet.row.goodwill

01085210337.19400
8677.2
9014
8853.9
8464.3
3473.1
3303.4
3255
2976
1661.8
1585.1
296.4
51.1
51.1
51.1
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

017378.115925.313433.2
11498.6
10966.2
9192.1
8274.5
3650.6
3245.8
2911.9
2639.4
1782.3
1705.1
533.9
209
200.1
208.4
210.3
197.5
179
114.6
97.9
39.3
48
20.7
0.9
0.5
0
0

balance-sheet.row.goodwill-and-intangible-assets

028230.126262.422833.1
20175.9
19980.2
18046
16738.8
7123.7
6549.2
6166.9
5615.5
3444
3290.2
830.3
260.1
251.2
259.6
210.3
197.5
179
114.6
97.9
39.3
48
20.7
0.9
0.5
0
0

balance-sheet.row.long-term-investments

023123.824620.519679
21801.2
22564
23443.5
20904.5
18801.5
17200.5
14371.1
11560.7
9822.5
10011.5
7960.7
6652.3
3683.8
3465.1
2704.8
0
2108.4
1187.1
741.6
760.6
570.3
219.3
46.1
1.7
0
0

balance-sheet.row.tax-assets

0624.5442.6265.6
244.9
196.1
173.1
144.5
129.6
102.5
101.2
88.1
31.5
16.7
18.4
11.4
12.9
11.8
5.6
0
20.1
36.5
322.4
15.5
-555.5
-211.5
10.6
10.3
0
0

balance-sheet.row.other-non-current-assets

05459.34531.26807.4
3376.5
1890.9
1763.9
810.8
644
259.3
351.6
316.9
347.9
295.9
377.5
37.6
28.5
42.3
22.3
2268.7
29.4
0
0
-2.4
576.3
223.8
4.9
16.3
0.2
0

balance-sheet.row.total-non-current-assets

07967771884.762869.2
58601.2
55716.3
52549.6
46914.5
33003.5
29876.3
26672.3
22488.6
17125.6
16241.7
10882.5
8220.2
5121.6
4917.9
4217.5
3706.8
3390.8
2115.5
1732.4
1162.4
899.7
427.8
137
70.4
4.6
3.3

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0113469.6107163.993293.8
83686
76119.6
70551.4
61971
43767.8
38201.7
35336.3
29475.2
25507.1
22290.8
16820.1
11527.1
7538.9
7435
6633.9
5668.7
5170.5
4218.8
3139.6
2207.3
1571.1
858.2
647.1
287.1
111.3
106.7

balance-sheet.row.account-payables

06159.662845063.7
3289
2397.3
2333.3
1781.9
1149.4
1048.6
905
1136.4
903.7
939.9
827.3
491.3
398
357.8
530.9
560.3
484
339.3
326.3
89.5
70.5
63.6
36.9
50.8
10.8
5.7

balance-sheet.row.short-term-debt

019555.117402.914547.6
14911.8
8920.5
10536.8
10478.2
5650.4
7334.2
3950.7
1424.2
875.3
2187.1
1830.4
1583
502.5
1556.4
1465.2
786.3
682
466.3
772.3
627.5
129.7
39.6
0
22.5
29.5
21

balance-sheet.row.tax-payables

0537929.8727.5
564.7
759.6
478.9
480.1
478.2
503.8
342.9
288.9
162
111.7
247.4
48.9
49.5
73.7
42.1
27.8
38
62.6
61.3
9.5
16.2
8
12.1
10.4
0
-0.1

balance-sheet.row.long-term-debt-total

015554.512844.99697.4
9103
12987.1
12670.1
9814.9
5571
3571.5
3856.7
4199.7
4280.2
3915.1
2758.3
1284.5
1180.5
746.8
545.1
981.2
752.8
1026.9
45.8
25.2
25.2
13.8
30.1
0.5
0.4
14.3

Deferred Revenue Non Current

0639.4632.4512.8
482.2
417.3
363.5
397.1
346.7
169.3
139.6
404.5
627.6
374.2
57.8
64.9
65.2
70.1
-449
-877.5
5.1
5.9
-38.8
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0125.29611.21528.6
54.6
249
4574.3
604.6
944.9
352.8
1337.1
309.5
729.9
221.9
110.6
67.6
541.3
44.1
18.8
40.1
33.6
34.1
32
27
16.4
9.2
37.3
0.6
22.7
34.1

balance-sheet.row.total-non-current-liabilities

023095.819756.915608.3
12829.4
19481.7
19035.4
15629.1
8408.9
6592.9
6696
6532.6
6309.3
5928.3
3723.4
2076.8
1337.8
900.5
642.4
1087.7
762.7
1035.3
53.9
25.2
27.9
13.8
42.1
0.5
0.4
14.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

02049.6745648.4
627.3
410.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

056853.35305544918.2
37701.7
36915.4
36958.6
32229.6
18517.5
17532.1
16233.3
11810.7
10202.5
10920
7426.9
4575.1
3093
3118.6
2985.3
2793.7
2356.7
2201.9
1466.2
884.7
352.6
201.1
116.4
154.5
79.3
81.1

balance-sheet.row.preferred-stock

01300.11198.41265.8
933.6
468
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

02672.42672.22562.9
2562.9
2562.9
2563.1
2495.1
2414.5
2314.1
2311.6
2240.5
2240.5
1904.4
1904.4
1237.8
1237.8
1237.8
952.1
832
826.5
381.9
381.9
293.8
293.8
226.1
150.7
58.8
20
20

balance-sheet.row.retained-earnings

024542.523216.921039.6
17505
15125.7
12771.5
11111.6
8993.8
6937
5457
7112.7
5703
4483.5
3717.7
3258.2
1184.8
715.1
262.9
349.3
411.3
372.5
182.1
143.4
108.6
114.4
46.8
27.5
6.2
2.9

balance-sheet.row.accumulated-other-comprehensive-income-loss

0-1300.1-1198.4-1265.8
-933.6
-468
-4436.3
-4000.5
-3047.9
-2592.5
-2164.5
-1671.5
-1213.5
-1061.4
-871.5
-654.1
-544.9
-478
0
-9
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

018469.918693.415589.5
16927.7
14199.5
17079.5
15720.6
13829.8
11523
11070.7
7650.6
6828.8
4445.4
3672.4
2634.7
2131.2
2397.4
1875.2
1218.6
1066.4
945.8
845.5
826.8
743.2
264.1
321.7
14.4
5.7
2.7

balance-sheet.row.total-stockholders-equity

045684.844582.539191.9
36995.5
31888.1
27977.7
25326.9
22190.2
18181.6
16674.8
15332.2
13558.8
9771.9
8423
6476.5
4008.9
3872.3
3090.2
2390.9
2304.1
1700.2
1409.5
1264
1145.5
604.5
519.1
100.7
32
25.6

balance-sheet.row.total-liabilities-and-stockholders-equity

0113469.6107163.993293.8
83686
76119.6
70551.4
61971
43767.8
38201.7
35336.3
29475.2
25507.1
22290.8
16820.1
11527.1
7538.9
7435
6633.9
5668.7
5170.5
4218.8
3139.6
2207.3
1571.1
858.2
647.1
287.1
111.3
106.7

balance-sheet.row.minority-interest

010931.59526.59183.6
8988.7
7316.1
5615
4414.6
3060.1
2488.1
2428.2
2332.3
1745.9
1599
970.2
475.5
437.1
444.1
558.3
484.2
509.7
316.7
263.9
58.7
73
52.6
11.6
32
0
0

balance-sheet.row.total-equity

056616.354108.948375.6
45984.3
39204.2
33592.7
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

025012.325549.123920.1
23771.3
23020.6
24059.6
21123.8
18850
17234.2
14404.9
11604.9
10047.3
10242.8
8179.4
6664
3683.9
3471
2706.9
2227.2
2113.6
1187.3
1026.9
760.6
570.3
219.3
46.1
1.7
0
0

balance-sheet.row.total-debt

035109.630247.724245
24014.8
21907.6
23206.9
20293.1
11221.3
10905.7
7807.4
5623.9
5155.5
6102.1
4588.7
2867.5
1683
2303.2
2010.3
1767.5
1434.8
1493.2
818.1
652.6
154.9
39.6
30.1
22.5
29.5
35.4

balance-sheet.row.net-debt

02141614006.413936.9
14053
12374.4
14660.4
13044.2
5225.3
6877.1
4111.7
2556.5
183
3207.6
1245.2
1570.8
677.3
1229.4
1021.1
1014.6
752
250.8
474
280.4
-188.5
-130.4
-299.7
-2.8
22.9
28.2

Naudas plūsmas pārskats

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. finanšu ainavā pēdējā laikā ir vērojamas ievērojamas izmaiņas brīvās naudas plūsmā, kas liecina par NaN pārmaiņām. Uzņēmums nesen palielināja savu pamatkapitālu, emitējot NaN, kas iezīmē NaN atšķirību salīdzinājumā ar iepriekšējo gadu. Uzņēmuma ieguldījumu darbības rezultātā neto naudas izlietojums pārskata valūtā sasniedza NaN. Tas ir NaN pieaugums salīdzinājumā ar iepriekšējo gadu. Tajā pašā periodā uzņēmums reģistrēja NaN, NaN un NaN, kas ir nozīmīgi, lai izprastu uzņēmuma ieguldījumu un atmaksas stratēģijas. Uzņēmuma finansēšanas darbības rezultātā neto naudas izlietojums bija NaN, un gada griezumā starpība bija NaN. Turklāt uzņēmums piešķīra NaN dividendēm akcionāriem. Tajā pašā laikā tas veica citus finanšu manevrus, kas minēti kā NaN, kas arī būtiski ietekmēja tā naudas plūsmu šajā periodā. Šīs sastāvdaļas kopā veido visaptverošu priekšstatu par uzņēmuma finansiālo stāvokli un stratēģisko pieeju naudas plūsmas pārvaldībai.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

02895.13947.54987.4
3940
3743.5
3019.9
3585.3
3221.3
2870.7
2369.8
2399.9
1839.3
1384.8
1000.3
2564.3
760.9
690.2
292.8
237.9
282.1
298.2
161.7
141.1
135.8
94.4
64.9

cash-flows.row.depreciation-and-amortization

02965.22335.91834.4
1666.2
1472.1
1320.1
938.6
732.9
649.3
558.4
415.5
286.2
209.9
152.7
134.7
132.5
136.5
132.1
116.7
91.1
56.1
37.6
28.6
28.1
20.1
9.3

cash-flows.row.deferred-income-tax

0-2723.50-4038.6
-2605.1
-2733
-1876.1
-2322.1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

035.954.564.3
55.2
109.1
72.3
10.4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-1081.2-1387.9259.7
-1401.4
-494.6
-535.1
-212.7
-288.1
-101.8
-555.3
-44.5
-28.2
-88.6
11
599.1
13.6
-133.7
-5.4
-107
789.2
23.2
-35
-45.2
0.8
-78
-10.8

cash-flows.row.account-receivables

01605.1-2076.6-1795
-1559.9
-863.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-333.9-1430.1-464.7
-1253.4
-505.2
-564.7
-491.1
-65.4
-88.3
-105
-149.6
-155.1
-99.8
-66.2
-70.1
-27.6
109.6
-42.7
-67
-27
56
-11.2
-37.5
12.4
-14.4
-4.9

cash-flows.row.account-payables

0-1605.12076.61795
1559.9
863.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-2352.442.2724.5
-148
10.6
29.6
278.4
-222.7
-13.4
-450.3
105.1
126.9
11.2
77.2
669.2
41.2
-243.3
37.2
-40
816.2
-32.8
-23.8
-7.7
-11.6
-63.6
-5.9

cash-flows.row.other-non-cash-items

01322.7-732.4841.5
924.9
1125.3
949
580.8
-1556.1
-1797.2
-1172.7
-1759.4
-1431.8
-1189.5
-960.6
-3036.2
-673.9
-561.5
-234.6
-59.3
-957.3
-227.3
-61.8
-56.3
-26.3
1.7
3.2

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-5336.7-5888.8-4972.6
-4437.1
-3962.1
-3174.9
-2170.6
-1922
-1235.5
-1119.4
-1040.1
-1160.6
-796.8
-339.2
-348.1
-210.6
-209.7
-266.6
-222.6
-205
-264.1
-139.5
-141.5
-126.6
-78
-52.2

cash-flows.row.acquisitions-net

0-923.7-487.6381.4
-140.3
-818.8
-622.6
-7822.6
-249.4
109.9
-1145.7
-2225.2
30.8
12.7
2.1
-2.6
22.8
9.3
18.2
279.9
11.6
25.5
4.9
10.8
17.6
1
0

cash-flows.row.purchases-of-investments

0-943-1501.3-1424.6
-1070.1
-517.9
-2133.4
-2525.7
-1395.7
-2955.3
-1943.2
-364.1
-759.1
-1500.3
-1190.2
-770.2
-563.2
-543.7
-399.3
-349
-665.1
-134.9
-475.3
-317.8
-345.5
-253.5
-46

cash-flows.row.sales-maturities-of-investments

02809.34649.52168.3
2037.2
4916.2
1243.4
1550.6
1492.6
2127
1515.9
1540.7
1484.7
615.5
1348
755.5
822.8
632.3
329.6
76.6
45.4
535.7
254.8
243.5
30.2
43.4
0.4

cash-flows.row.other-investing-activites

0574.8-835.9-9.5
-1095.8
210.6
-557.4
464.2
-372.6
83.9
214.2
285.2
-574.4
-97.6
-85
-32.5
-15.6
58
-17
-222.6
33.9
-0.2
204.6
-282
-19.3
48.2
-2

cash-flows.row.net-cash-used-for-investing-activites

0-3819.3-4064-3857
-4706.2
-172
-5244.9
-10504.1
-2447.1
-1869.9
-2478.3
-1803.5
-978.6
-1766.5
-264.3
-397.8
56.1
-53.7
-335.1
-437.7
-779.2
162.1
-150.5
-487.1
-443.6
-238.9
-99.8

cash-flows.row.debt-repayment

0-21146.2-26280.1-27391.9
-15707.8
-13942.1
-9995.1
-9085.3
-9956.1
-7239.7
-2559.5
-2417.6
-3795.9
-4042.2
-2081.7
-1071.9
-1410.2
-1753.9
-1221
-817.9
-727.4
-665.6
-1613.8
-716.1
-311.2
-62.8
-52.4

cash-flows.row.common-stock-issued

0000
0
0
4851.4
3017.6
2728.5
116.1
1466.1
30.5
3151.1
0
637.8
18.9
16.1
17.2
0
0
9
951.5
8.4
6.7
437.6
0
372.4

cash-flows.row.common-stock-repurchased

0000
0
0
0
14821.2
7694.5
8990.2
4017.4
2105.1
-17.8
0
3083.4
1703.6
1286
2100.3
0
0
873.7
-589.4
1691
1200.8
-48.5
0
-342.4

cash-flows.row.dividends-paid

0-2455.2-2374.4-1914
-1834.6
-1864.4
-1775.5
-1433.5
-1193.5
-1109.3
-962.7
-804.5
-500.9
-437.3
-297.4
-268.6
-257.9
-237.6
-371.9
-200
-149.2
-94.9
-89.8
-78.2
-14.1
-13.4
-9.7

cash-flows.row.other-financing-activites

022265.13308328474.6
19009.5
13870.5
10056.8
2588.7
2172.7
-206.6
-98.3
154.3
3231.9
5392.5
480.3
18.9
16.1
17.2
1963.6
1165.7
8.5
984.4
24.1
41
402.5
117.1
369.8

cash-flows.row.net-cash-used-provided-by-financing-activities

0-1336.24428.5-831.3
1467.1
-1936
3137.5
9908.6
1446
550.7
1863.1
-932.1
2068.4
913
1822.5
401
-349.9
143.1
370.7
147.8
14.6
586.1
19.9
454.2
466.3
41
337.7

cash-flows.row.effect-of-forex-changes-on-cash

073.6128.3-134.7
-300.2
-5.1
-18
-172.5
80.5
36.6
8.9
-31.4
-12
-6
-3.8
-0.7
-4.6
-4.8
-1.2
-0.4
0
-0.1
0
0
0.1
0
0

cash-flows.row.net-change-in-cash

0-1667.74710.3-874.2
-959.5
1109.4
824.7
1812.3
1189.4
338.4
593.9
-1755.3
1743.4
-542.9
1757.7
264.3
-65.4
216.1
219.3
-102
-559.5
898.3
-28.2
35.3
161.2
-159.7
304.5

cash-flows.row.cash-at-end-of-period

09502.411170.16450.7
7324.9
8284.4
7175
6350.3
4538
3348.6
3010.2
2416.3
4171.6
2428.2
2971.1
1213.4
949.1
1014.4
800.2
580.9
682.9
1242.4
344.1
372.3
343.4
170
329.8

cash-flows.row.cash-at-beginning-of-period

011170.16459.77324.9
8284.4
7175
6350.3
4538
3348.6
3010.2
2416.3
4171.6
2428.2
2971.1
1213.4
949.1
1014.4
798.4
580.9
682.9
1242.4
344.1
372.3
337
182.2
329.8
25.3

cash-flows.row.operating-cash-flow

03414.24217.63948.7
2579.8
3222.4
2950.1
2580.2
2110
1621
1200.2
1011.6
665.5
316.6
203.4
261.9
233
131.5
184.9
188.3
205.1
150.1
102.5
68.2
138.4
38.2
66.6

cash-flows.row.capital-expenditure

0-5336.7-5888.8-4972.6
-4437.1
-3962.1
-3174.9
-2170.6
-1922
-1235.5
-1119.4
-1040.1
-1160.6
-796.8
-339.2
-348.1
-210.6
-209.7
-266.6
-222.6
-205
-264.1
-139.5
-141.5
-126.6
-78
-52.2

cash-flows.row.free-cash-flow

0-1922.5-1671.3-1023.8
-1857.3
-739.6
-224.8
409.6
188.1
385.5
80.8
-28.4
-495.1
-480.2
-135.8
-86.2
22.4
-78.2
-81.7
-34.3
0.1
-113.9
-37
-73.4
11.8
-39.8
14.3

Peļņas vai zaudējumu aprēķina rinda

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ieņēmumi salīdzinājumā ar iepriekšējo periodu mainījās par NaN%. Tiek ziņots, ka 2196.HK bruto peļņa ir NaN. Uzņēmuma darbības izdevumi ir NaN, kas salīdzinājumā ar iepriekšējo gadu ir mainījušies par NaN%. Nolietojuma un amortizācijas izdevumi ir šādi NaN, kas ir NaN% izmaiņas salīdzinājumā ar iepriekšējo pārskata periodu. Tiek ziņots, ka darbības izdevumi ir NaN, kas uzrāda NaN% izmaiņas gada laikā. Pārdošanas un mārketinga izdevumi ir NaN, kas ir NaN% izmaiņas salīdzinājumā ar iepriekšējo gadu. EBITDA, pamatojoties uz jaunākajiem skaitļiem, ir NaN, kas veido NaN% pieaugumu salīdzinājumā ar iepriekšējo gadu. Pamatdarbības ienākumi ir NaN, kas uzrāda NaN% izmaiņas, salīdzinot ar iepriekšējo gadu. Tīro ienākumu izmaiņas ir NaN%. Pagājušā gada neto ienākumi bija NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

041399.543951.539005.1
30307
28585.2
24918.3
18533.6
14628.8
12608.6
12025.5
9996.4
7340.8
6485.5
4555.4
3872.3
3773.2
3693.3
3102
2988.5
2425.4
2154.6
1031.7
727.8
579.5
442.5
340.4
190.3
92.7
64.7

income-statement-row.row.cost-of-revenue

021595.323169.720228.3
13431.2
11543.4
10365.3
7609
6718.4
6308
6718.6
5543.4
4126.8
3991.1
2984.6
2610.7
2711.9
2693.8
2282.2
2076
1651.9
1564
668.1
448.9
307.6
248.4
209.3
116.5
65.3
50.1

income-statement-row.row.gross-profit

019804.220781.918776.8
16875.8
17041.7
14553
10924.6
7910.5
6300.6
5307
4453
3214
2494.4
1570.9
1261.6
1061.4
999.5
819.8
912.5
773.6
590.5
363.6
279
271.9
194
131.1
73.9
27.3
14.5

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0-17.92683.72276.4
1841.5
1666
44.1
-13.2
181.9
78.3
324.6
97.9
89.9
158.8
62.1
56
30.9
21.9
60.5
96.5
52.8
42.7
18.1
12.3
18.9
10.9
8
10
-0.3
0.5

income-statement-row.row.operating-expenses

018240.91714516055.8
14045.6
14425.7
12185.7
8621
6168.5
4827.1
4114.5
3339.1
2620.4
2149
1394.5
1098.2
939.7
834.5
794.6
829.5
658.2
549.4
304.1
206.9
172.3
102.3
62.6
31.6
14.3
4.9

income-statement-row.row.cost-and-expenses

039836.240314.736284.1
27476.8
25969.1
22551
16230
12886.8
11135.2
10833.1
8882.5
6747.2
6140.2
4379.1
3708.8
3651.6
3528.3
3076.7
2905.5
2310.1
2113.4
972.2
655.7
480
350.7
271.9
148.1
79.6
55

income-statement-row.row.interest-income

0363.6282.6233.7
199.6
186.6
145.7
79.2
80.9
56.2
69.8
63.8
29.7
51.6
19.6
14.5
17.9
12.5
13.8
17.5
13.7
8.7
2.9
13.7
8.1
0
0
0
0
0

income-statement-row.row.interest-expense

01324.8963.8822.5
881
1074.7
929.7
577.5
488.2
470
415
350.5
370.6
314
162.4
132.4
149.6
130.6
83.3
72
37
45.9
36.2
23.7
9.8
-6.1
-3.3
3.1
3
1.5

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-42.9-3722.2-259.9
-43.3
-1887.5
1212.3
1758.1
1829.5
1898.4
1525.6
1792.3
1529.5
1381.3
1025.6
3101.2
714
591.4
249.1
124.7
159.4
282.5
104.1
76.8
42.6
12.8
5.2
-3.1
-3.1
-1.4

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0-17.92683.72276.4
1841.5
1666
44.1
-13.2
181.9
78.3
324.6
97.9
89.9
158.8
62.1
56
30.9
21.9
60.5
96.5
52.8
42.7
18.1
12.3
18.9
10.9
8
10
-0.3
0.5

income-statement-row.row.total-operating-expenses

0-42.9-3722.2-259.9
-43.3
-1887.5
1212.3
1758.1
1829.5
1898.4
1525.6
1792.3
1529.5
1381.3
1025.6
3101.2
714
591.4
249.1
124.7
159.4
282.5
104.1
76.8
42.6
12.8
5.2
-3.1
-3.1
-1.4

income-statement-row.row.interest-expense

01324.8963.8822.5
881
1074.7
929.7
577.5
488.2
470
415
350.5
370.6
314
162.4
132.4
149.6
130.6
83.3
72
37
45.9
36.2
23.7
9.8
-6.1
-3.3
3.1
3
1.5

income-statement-row.row.depreciation-and-amortization

02965.22335.92986.4
2171.8
1472.1
1320.1
938.6
732.9
649.3
558.4
415.5
286.2
209.9
152.7
134.7
132.5
136.5
132.1
116.7
91.1
56.1
37.6
28.6
28.1
20.1
9.3
-7
3.3
1

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

03307.58296.66313.7
4721.1
6413.2
3535.5
4074.9
3399.4
3297.2
2394.3
2818.8
2036
1580.5
1140.5
3212
807.6
736.7
347.1
234.5
298.2
329.4
168.5
144.1
141.9
106.3
77.3
49.3
9.8
8.7

income-statement-row.row.income-before-tax

03264.64574.46053.8
4677.8
4525.8
3579.6
4061.7
3571.5
3371.8
2718.1
2906.3
2123
1726.7
1202
3264.7
835.7
756.4
341
269.3
312.9
347.8
175.1
152.7
151.4
110.9
79.5
49.3
9.7
8.7

income-statement-row.row.income-tax-expense

0369.5626.91066.4
737.9
782.2
559.7
476.5
350.2
501.2
348.2
506.3
283.8
341.8
201.6
700.4
74.7
66.2
48.2
31.4
30.8
49.6
13.6
11.6
15.7
16.5
12.9
9.1
3.4
2.7

income-statement-row.row.net-income

02386.33730.84728.7
3662.8
3321.6
2707.9
3124.5
2805.8
2460.1
2112.9
2027.1
1563.9
1165.6
863.7
2498.2
690.9
625.8
259.2
159
215.3
263.6
147.2
135.5
128.5
92.2
63.7
36
6.4
6

Biežāk uzdotie jautājumi

Kas ir Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) kopējie aktīvi?

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) kopējie aktīvi ir 113469604813.000.

Kādi ir uzņēmuma gada ieņēmumi?

Gada ieņēmumi ir N/A.

Kāda ir uzņēmuma peļņas norma?

Uzņēmuma peļņas norma ir 0.475.

Kāda ir uzņēmuma brīvā naudas plūsma?

Brīvā naudas plūsma ir -0.539.

Kāda ir uzņēmuma neto peļņas norma?

Neto peļņas norma ir 0.049.

Kādi ir uzņēmuma kopējie ieņēmumi?

Kopējie ieņēmumi ir 0.071.

Kāda ir Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) tīrā peļņa (tīrie ienākumi)?

Tīrā peļņa (tīrie ienākumi) ir 2386265813.000.

Kāds ir uzņēmuma kopējais parāds?

Kopējais parāds ir 35109563838.000.

Kāds ir pamatdarbības izdevumu skaits?

Darbības izdevumi ir 18240906770.000.

Kāds ir uzņēmuma skaidrās naudas rādītājs?

Uzņēmuma nauda ir 0.000.